- Previous Close
6.43 - Open
6.38 - Bid 6.17 x 400
- Ask 6.22 x 200
- Day's Range
6.10 - 6.49 - 52 Week Range
5.03 - 12.22 - Volume
1,073,927 - Avg. Volume
1,975,911 - Market Cap (intraday)
466.53M - Beta (5Y Monthly) 2.40
- PE Ratio (TTM)
-- - EPS (TTM)
-1.54 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.50
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
www.mindmed.coRecent News: MNMD
View More
Performance Overview: MNMD
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNMD
View MoreValuation Measures
Market Cap
466.53M
Enterprise Value
214.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.93
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.44%
Return on Equity (ttm)
-68.01%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-108.68M
Diluted EPS (ttm)
-1.54
Balance Sheet and Cash Flow
Total Cash (mrq)
273.74M
Total Debt/Equity (mrq)
9.05%
Levered Free Cash Flow (ttm)
-44.56M